Results 1 to 10 of about 402,161 (308)

Epigenetic remodeling via HDAC6 inhibition amplifies anti-tumoral immune responses in myeloid leukemia cells [PDF]

Cell Death and Disease
Histone deacetylase 6 (HDAC6) has emerged as a promising therapeutic target in cancer due to its immunomodulatory effects. While its prognostic significance remains debated, we demonstrate that HDAC6 loss significantly impairs myeloid leukemia ...
Julian Schliehe-Diecks, Jia-Wey Tu, Pawel Stachura, Katerina Schaal, Marie Kemkes, Eleni Vasileiou, Nadine Rüchel, Danielle Brandes, Melina Vogt, Thomas Lenz, Adarsh Nair, Stefanie Scheu, Pilar M. Dominguez, Agata Pastorczak, Karin Nebral, Kai Stühler, Ute Fischer, Aleksandra A. Pandyra, Arndt Borkhardt, Sanil Bhatia   +19 more
doaj   +2 more sources

Long-term experience in treatment of acute promyelocytic leukemia in Mexican children in a tertiary care hospital

Frontiers in Oncology, 2023
IntroductionAcute promyelocytic leukemia (APL) is a rare myeloid leukemia subtype affecting adult and pediatric populations. APL constitutes 15-20% of all childhood AML in Latin America, compared to 7% in the non-Latino population.
Marco Antonio Murillo-Maldonado, Paulina González Galván, Israel Parra Ortega, Félix Gaytán Morales, Félix Gaytán Morales, Luis Juárez Villegas, Elisa Dorantes Acosta, Elisa Dorantes Acosta   +7 more
doaj   +1 more source

Integrating genetic and epigenetic factors in chronic myeloid leukemia risk assessment: toward gene expression-based biomarkers

Haematologica, 2021
Cancer treatment is constantly evolving from a one-size-fits-all towards bespoke approaches for each patient. In certain solid cancers, including breast and lung, tumor genome profiling has been incorporated into therapeutic decision-making. For chronic
Vaidehi Krishnan, Dennis Dong Hwan Kim, Timothy P. Hughes, Susan Branford, S. Tiong Ong   +4 more
doaj   +1 more source

Influence of Telomere Length on the Achievement of Deep Molecular Response With Imatinib in Chronic Myeloid Leukemia Patients

HemaSphere, 2021
Tyrosine kinase inhibitors have dramatically changed the outcome of chronic myeloid leukemia (CML), and nowadays, one of the main treatment goals is the achievement of deep molecular responses (DMRs), which can eventually lead to therapy discontinuation ...
Natalia Estrada, Blanca Xicoy, Fabian Beier, Olga Garcia, Cristian Morales, Concepción Boqué, Miguel Sagüés, Mónica S. Ventura Ferreira, Rolando Vallansot, Sílvia Marcé, Marta Cabezón, Tim H. Brümmendorf, Lurdes Zamora   +12 more
doaj   +1 more source

Socioeconomic cost of AML in Sweden—A population‐based study using multiple nation‐wide registers

eJHaem, 2021
Acute myeloid leukemia (AML) is associated with a high economic and clinical burden. Recently novel therapies have been added to standard treatment regimens. Here, we evaluated the economic impact of AML up until the introduction of these novel therapies.
Emma Hernlund, Josefine Redig, Björn Paulsson, Åsa Rangert Derolf, Martin Höglund, Simona Vertuani, Gunnar Juliusson   +6 more
doaj   +1 more source

Acute myeloid leukemia: update in diagnosis and treatment in Brazil [PDF]

Einstein (São Paulo), 2011
Objective: To identify how the Brazilian hematology centers treated and diagnosed cases of acute myeloid leukemia in 2009. Methods: An epidemiological observational multicenter study of 11 listed Brazilian centers that treat acute myeloid leukemia and ...
Ricardo Helman, Fabio Pires de Souza Santos, Belinda Simões, Elias Hallack Atta, Fernando Callera, Jane de Almeida Dobbin, Éderson Roberto Mattos, Angelo Atalla, Angelo Maiolino, Maria Aparecida Zanichelli, Cristiane Fração Diefenbach, Marcia Torresan Delamain, Nelson Hamerschlak   +12 more
doaj   +3 more sources

Radiation-induced myeloid leukemia in murine models. [PDF]

, 2014
The use of radiation therapy is a cornerstone of modern cancer treatment. The number of patients that undergo radiation as a part of their therapy regimen is only increasing every year, but this does not come without cost.
Davoren, Michael, Rivina, Leena, Schiestl, Robert H   +2 more
core   +2 more sources

Preferential expression of the transcription coactivator HTIF1alpha gene in acute myeloid leukemia and MDS-related AML [PDF]

, 2002
HTIF1α, a transcription coactivator which is able to mediate RARα activity and functionally interact with PML, is encoded by a gene on chromosome 7q32–34, which is a critical region in acute myeloid leukemias (AML). With the assumption that this gene may
AGUIARI, Gianluca, CASTOLDI, GL, CUNEO, Antonio, DE ANGELI, C, DEL SENNO, Laura, GANDINI, D, LANZA, F, MANZATI, E, PANDOLFI, PP   +8 more
core   +1 more source

Acute Myeloid Leukemia

Apollo Medicine, 2004
AbstractAdvances in our understanding of the pathophysiology of acute myeloid leukemia (AML) have not yet led to major improvements in disease-free and overall survival of adults with this disease. Only about one-third of those between ages 18–60 who are diagnosed with AML can be cured; disease-free survival is rare and current therapy devastating in ...
Richard M, Stone, Margaret R, O'Donnell, Mikkael A, Sekeres   +2 more
openaire   +3 more sources

Downregulating Notch counteracts KrasG12D-induced ERK activation and oxidative phosphorylation in myeloproliferative neoplasm. [PDF]

, 2019
The Notch signaling pathway contributes to the pathogenesis of a wide spectrum of human cancers, including hematopoietic malignancies. Its functions are highly dependent on the specific cellular context. Gain-of-function NOTCH1 mutations are prevalent in
Chang, Yuan-I, Hofmann, Inga, Kong, Guangyao, Letson, Christopher, Liu, Yangang, Loh, Mignon, Padron, Eric, Pear, Warren S, Qian, Shuiming, Rajagopalan, Adhithi, Ranheim, Erik A, Stieglitz, Elliot, Wen, Zhi, Yang, David, You, Xiaona, Zhang, Jing, Zhang, Jingfang, Zhang, Xinmin, Zhong, Xuehua, Zhou, Lan, Zhou, Yun   +20 more
core   +1 more source